Dexmedetomidine in Modifying Immune Paralysis In Patient With Septic Shock

• Status: Unknown status
• Trial end date: 2020-03-20
• Target enrollment: 0
• Participant gender: All

Summary

in this study the investigators aim to assess the role of using dexmedetomidine as sedative in septic shock patients in comparison with midazolam. The investigators aim to assess the effect on immune response and inflammatory mediators and effect on vasopressors.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kasr El Aini Hospital
• Treatments: Dexmedetomidine; Midazolam

Criteria

Inclusion Criteria:

• Age more than 18 years old

• All mechanically ventilated patients who will be clinically suspected of having septic shock defined by infusion of at least one vasopressor and lactate > 2.0 mmol/l (5)

Exclusion Criteria:

• Age < 18 years old

• Pregnant patient

• Source of sepsis not controlled

• Acute hepatitis or severe liver disease (Child-Pugh class C)

• Left ventricular ejection fraction less than 30%

• Heart rate less than 50 beats/min

• Second or third degree heart block

• Systolic pressure < 90 mmHg despite of infusion of 2 vasopressors.

• Psychological illness or severe cognitive dysfunction

• Patients who are allergic to dexmedetomidine